APA (7th ed.) Citation

AE, E., SS, S., HA, I., MF, H., & SE, A. (2020). Targeting MDR-1 gene expression, BAX/BCL2, caspase-3, and Ki-67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity. Fundamental & clinical pharmacology, 34(4), 458. https://doi.org/10.1111/fcp.12549

Chicago Style (17th ed.) Citation

AE, El-Sisi, Sokkar SS, Ibrahim HA, Hamed MF, and Abu-Risha SE. "Targeting MDR-1 Gene Expression, BAX/BCL2, Caspase-3, and Ki-67 by Nanoencapsulated Imatinib and Hesperidin to Enhance Anticancer Activity and Ameliorate Cardiotoxicity." Fundamental & Clinical Pharmacology 34, no. 4 (2020): 458. https://doi.org/10.1111/fcp.12549.

MLA (9th ed.) Citation

AE, El-Sisi, et al. "Targeting MDR-1 Gene Expression, BAX/BCL2, Caspase-3, and Ki-67 by Nanoencapsulated Imatinib and Hesperidin to Enhance Anticancer Activity and Ameliorate Cardiotoxicity." Fundamental & Clinical Pharmacology, vol. 34, no. 4, 2020, p. 458, https://doi.org/10.1111/fcp.12549.